CA
TARA icon

Cliff Asness’s Protara Therapeutics TARA Stock Holding History

Cliff Asness’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$798K Buy
208,969
+142,164
+213% +$676K ﹤0.01% 3135
2026
Q1 		$348K Buy
66,805
+52,124
+355% +$309K ﹤0.01% 3335
2025
Q4 		$78.3K Buy
+14,681
New +$81.6K ﹤0.01% 3479

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Cliff Asness's TARA Position: Q2 2026 in Review

Cliff Asness increased its Protara Therapeutics (TARA) stake by 213% in Q2 2026, buying an estimated $676K and bringing the position to 208,969 shares worth $798K. The position accounts for ﹤0.01% of the portfolio, ranked #3135.

Cliff Asness first reported a position in TARA in Q4 2025 and has held it in 3 quarters since. 118 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Cliff Asness held 208,969 shares of Protara Therapeutics worth $798K as of Q2 2026.
  • Cliff Asness bought 142,164 Protara Therapeutics shares in Q2 2026, an estimated $676K.
  • Protara Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3135 holding.
  • Cliff Asness first reported a position in Protara Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 118 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.